. | . |
WHO authorises China's CanSinoBIO Covid-19 vaccine By Robin MILLARD Geneva (AFP) May 19, 2022 The World Health Organization on Thursday gave the green light to Chinese manufacturer CanSinoBIO's Covid-19 vaccine -- the ninth jab to get the WHO seal of approval. The WHO granted emergency use listing (EUL) authorisation to the single-shot Convidecia vaccine as China battles a resurgence of the virus triggered by the Omicron variant. It is the third Chinese-made vaccine to be approved by the UN's health agency, after Sinovac and Sinopharm. Convidecia was found to have 64 percent efficacy against symptomatic disease and 92 percent efficacy against severe Covid-19, the WHO said. "The vaccine meets WHO standards for protection against Covid-19 and ... the benefits of the vaccine far outweigh risks," the UN health agency said in a statement. The WHO's vaccine experts recommended it for people aged 18 and above. Convidecia may be used as a booster dose following a completed primary series using any other EUL Covid-19 vaccine, said the WHO. - Traditional vector method - The jab has already been rolled out in several countries including China, Argentina, Chile, Malaysia, Mexico and Pakistan. By the end of 2021, more than 58 million people had already been vaccinated with the jab, including nearly 14 million in China, the WHO said. The WHO has now given EUL status to nine Covid-19 vaccines and variations thereof -- Pfizer/BioNTech, AstraZeneca, Janssen, Moderna, Sinovac, Sinopharm, Bharat Biotech, Novavax and CanSinoBIO. Convidecia is based on a modified human adenovirus. The AstraZeneca and Janssen vaccines are also both based on viral vector technology. The more traditional approach uses a genetically-engineered version of the common cold adenovirus as a "vector" to shuttle genetic instructions into human cells. Convidecia "demonstrates a favourable safety profile in people across different age groups", eliciting strong immune responses with both binding and neutralising antibodies, said the WHO. - Stamp of approval - The EUL process studies the quality, safety and efficacy of vaccines and involves manufacturing site inspections. The WHO says EUL approval gives countries, funders, procuring agencies and communities assurance that the vaccine has met international standards. WHO's listing paves the way for countries to approve and import a vaccine for distribution quickly, especially those without an international-standard regulator of their own. It also opens the door for the jabs to enter the Covax global vaccine-sharing facility, which aims to provide equitable access to doses around the world, particularly in poorer countries. The WHO began reviewing rolling data on the CanSinoBIO vaccine in August. Other vaccines are also on the path towards an EUL decision, with the WHO studying rolling data on another Sinopharm jab, and vaccines from France's Sanofi, China's Clover and Zhifei Longcom, and Iran's Shifa Pharmed. The EUL process on Russia's Sputnik V jab has stalled. Hundreds of candidate vaccines are being worked on in laboratories around the world. The WHO is aware of 156 that have been in clinical development -- tested on humans -- and 198 that are in the pre-clinical phase. rjm/rl
North Korea sent planes to China for Covid supplies: reports Seoul (AFP) May 19, 2022 North Korea sent three of its largest cargo planes to China to pick up medical supplies to help with a spiralling Covid outbreak, local media reports say. Pyongyang announced its first-ever Covid cases last week and has since reported nearly two million cases of "fever" and 63 deaths as the virus tears through its unvaccinated population. State media reports do not specify how many of the cases and deaths have tested positive for Covid, but experts say the country's crumbling health system would ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |